arrow
L

Luciane Cruz Lopes

Lanzhou University
H指数:36
被引数:5,762

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Instruments for assessing healthcare professionals’ knowledge, attitudes and practices regarding deprescribing: a scoping review

评估医疗专业人员关于药物减量相关知识、态度和实践的仪器:一项范围综述

2026-08-210
OAAI
Improving communication about dietary fats: development and validation of the Fats-Related Attitude Scale based on data from Brazil, China, Croatia, Poland, and Spain

改进关于膳食脂肪的沟通:基于巴西、中国、克罗地亚、波兰和西班牙数据的脂肪相关态度量表的开发与验证

2026-06-011
PRE
Efficacy and Safety of Second-Generation Antipsychotics for Irritability Associated With Autism Spectrum Disorder: A Systematic Review and Network Meta-Analysis

第二代抗精神病药治疗与自闭症谱系障碍相关的易怒症状的疗效与安全性:一项系统评价和网络Meta分析

2026-05-241
PREAI
Identifying the Initiation of a New Line of Therapy for Metastatic Lung, Breast, and Colorectal Cancer in Real-World Data: A Scoping Review

基于真实世界数据识别转移性肺癌、乳腺癌和结直肠癌新治疗方案启动的起始点:一项范围综述

2026-04-270
OAAI
Comprehensive framework for prioritisation of health technologies for updating of essential medicines list to primary healthcare engaging stakeholders: a mixed-methods study protocol

参与利益相关者的基本药物清单更新卫生技术优先的综合框架: 混合方法研究协议

2025-10-290
OA
Mapping health evidence ecosystem in Brazil: a mixed-methods study protocol for developing a framework

绘制巴西健康证据生态系统地图:一种用于开发框架的混合方法研究方案

2025-10-240
OAAI
Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis

预防复发性静脉血栓栓塞症的一级/二级治疗持续时间:一项系统评价和Meta分析

2025-04-080
OA
Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison

13个监管机构批准的生物仿制药: 跨国比较

2023-10-012
OAAI